摘要
目的比较华法林在非瓣膜性心房颤动患者中的抗凝疗效及安全性。方法 2007年11月～2010年9月在我院门诊及住院的非瓣膜性心房颤动患者156例,随机分为华法林组及阿司匹林组各78例。比较两组患者血栓栓塞等终点事件和不良反应发生率。结果华法林组血栓栓塞等终点事件发生率显著低于阿司匹林组(P<0.05),两组不良反应发生率差异无统计学意义(P>0.05)。结论华法林对非瓣膜性心房颤动患者的抗凝疗效优于阿司匹林组。
Objective To explore the antithrombotic effects and safety of warfarin in nonvalvular atrial fibrillation. Methods From November 2007 to September 2010 in our hospital inpatient and outpatient nonvalvular atrial fibrillation patients of 156 cases were randomly divided into two groups, warfarin group and aspirin group,78 cases each. Compared between the two groups were thromboembolism and end events and adverse reaction rate. Results In warfarin group,incidence rate of thromboembolism were significantly lower than aspirin group （P 〈 0.05）, and there was no difference in incidence rate of adverse drug reaction between aspin group and warfarin group （P 〉 0.05）. Conclusion Warfarin is more effective than aspirin for prevention of thromboembolism events in patients with nonvalvular atrial fibrillation.
出处
《中国现代医生》
2013年第9期143-145,共3页
China Modern Doctor
基金
2012年浙江省卫生厅科技项目(2012KYB212)
关键词
非瓣膜性心房颤动
华法林
国际标准化比值
Nonvalvular atrial fibrillation
Warfarin
International standardization ratio
